Magnetic Resonance Imaging (MRI) involves three substances that could be the cause for a fatal, albeit rare condition, warned US Food and Drug Administration (FDA).

The labels, said the agency, "will emphasize the need to screen patients to detect these types of kidney dysfunction before administration."
The three intravenous drugs involved in the FDA action are Magnevist, Omniscan, and Optimark, which are used ahead of MRIs to help detect abnormalities of body organs, blood vessels and other tissues.
Source-AFP
MEDINDIA




Email






